Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern
In the absence of virus-targeting small-molecule drugs approved for the treatment and
prevention of COVID-19, broadening the repertoire of potent SARS-CoV-2-neutralizing …
prevention of COVID-19, broadening the repertoire of potent SARS-CoV-2-neutralizing …
Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals
The COVID-19 pandemic is a major threat to global health for which there are only limited
medical countermeasures, and we lack a thorough understanding of mechanisms of …
medical countermeasures, and we lack a thorough understanding of mechanisms of …
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
Abstract Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2
(SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results …
(SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results …
Safety, virologic efficacy, and pharmacokinetics of CT-P59, a neutralizing monoclonal antibody against SARS-CoV-2 spike receptor-binding protein: two randomized …
JY Kim, YR Jang, JH Hong, JG Jung, JH Park… - Clinical Therapeutics, 2021 - Elsevier
Purpose Neutralizing antibodies can reduce SARS-CoV-2 cellular entry, viral titers, and
pathologic damage. CT-P59 (regdanvimab), a SARS-CoV-2 neutralizing monoclonal …
pathologic damage. CT-P59 (regdanvimab), a SARS-CoV-2 neutralizing monoclonal …
A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope
With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants with increased transmissibility and potential resistance, antibodies and vaccines …
variants with increased transmissibility and potential resistance, antibodies and vaccines …
Broadly-neutralizing antibodies against emerging SARS-CoV-2 variants
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
have become a major concern in the containment of current pandemic. The variants …
have become a major concern in the containment of current pandemic. The variants …
[HTML][HTML] A highly potent antibody effective against SARS-CoV-2 variants of concern
C Fenwick, P Turelli, L Perez, C Pellaton… - Cell reports, 2021 - cell.com
Control of the ongoing SARS-CoV-2 pandemic is endangered by the emergence of viral
variants with increased transmission efficiency, resistance to marketed therapeutic …
variants with increased transmission efficiency, resistance to marketed therapeutic …
Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers
K Vanshylla, C Fan, M Wunsch, N Poopalasingam… - Cell host & …, 2022 - cell.com
A fraction of COVID-19 convalescent individuals mount a potent antibody response to SARS-
CoV-2 with cross-reactivity to SARS-CoV-1. To uncover their humoral response in detail, we …
CoV-2 with cross-reactivity to SARS-CoV-1. To uncover their humoral response in detail, we …
AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults
Y Cai, S Diallo, K Rosenthal, K Ren, DJ Flores… - Science Translational …, 2024 - science.org
The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
resulted in variants that can escape neutralization by therapeutic antibodies. Here, we …
resulted in variants that can escape neutralization by therapeutic antibodies. Here, we …
Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies
Neutralizing monoclonal antibodies (nAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) represent promising candidates for clinical intervention against …
coronavirus 2 (SARS-CoV-2) represent promising candidates for clinical intervention against …